News

OKYO Pharma’s executive chairman–linked entity has increased its position in the company, with Panetta Partners acquiring 82,018 additional ordinary...

XOMA Royalty Corporation has completed its acquisition of Lava Therapeutics N.V., purchasing all outstanding shares for $1.04 in cash...

Mesoblast will run a pivotal Phase 3 trial with the NIH-funded Blood and Marrow Transplant Clinical Trials Network to...

BioSyent posted double‑digit growth in Q3 2025, extending a profitable run built on in‑licensed, proven brands. Total company sales...

Actimed Therapeutics has licensed exclusive rights to develop and commercialize its cachexia pipeline, including lead candidate s-pindolol benzoate (ACM-001.1),...

AnaptysBio has expanded its stock repurchase capacity, authorizing up to $100 million of additional buybacks through March 31, 2026,...

AnaptysBio has filed a verified complaint in Delaware Chancery Court alleging that Tesaro, now part of GSK, breached a...

Iovance Biotherapeutics has granted inducement stock options covering 164,900 shares to 11 new non-executive employees, effective November 20, 2025....

Inventiva has extended its cash runway into late Q1 2027 after completing a U.S. public offering in November that...